Hikal Ltd Q4 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/q5t267hors6n19wndsbstndg.pdf

Key Takeaways


Crop Protection: The Overhang

Sameer Hiremath: "I've spoken to each and every one of my customers in the world. I asked them this question. They said, 'Your guess is as good as mine.'"

Pharma: The Margin Recovery Story

Manoj Mehrotra: "Definitely, 12-15% top line growth, that is our plan."

CDMO & New Growth Engines

Sameer Hiremath: "Customers and regulatory authorities on the pharma side are reluctant to go into China. And we're seeing in companies in India, like, Hikal will benefit from increased traction."

CAPEX, Capacity & Returns


Margins & Return Profile

Sameer Hiremath: "Once this full capacity gets utilized and comes on stream in the next couple of years, we can see our ROCE will go up and closer to the high teens and margins will go, which is the most important metrics, our EBITDA margins will go in excess of 20%."

Guidance & Commitments

CommitmentSpecificsTimeline
CDMO destocking normalizationIndustry normalization expected toward end of H1End of H1 FY25
Crop protection recoveryMarket trajectory to improve; conservative case is toward end of H2End of H2 FY25
Crop protection pricing improvementCustomers expect marginal pricing improvement once inventory liquidates and fresh orders start6-9 months
Pharma topline growth12-15% topline growth plan3-5 year horizon
Revenue targetAchieve ₹3,000 crores revenue3-4 years
Revenue targetAchieve ₹6,000 crores revenueBefore FY30
EBITDA marginReturn to 20%+Next couple of years
ROCEMove closer to high teensNext couple of years
Animal health commercial suppliesValidation takes 14-18 months; commercial quantities expectedNext 2 years
Animal health critical sizeBusiness to reach critical sizeNext 2-3 years
Food ingredients peak revenueTwo products reach peak revenue2026
KSM Phase-III moleculesReach full potential2026 or 2027
All businesses return to pre-COVID levelsGrowth and return to pre-COVID-type levelsNext 2-3 years
CDMO mix normalizationReturn to ~50:50 CDMO:API mix once Phase-III molecules launchAt Phase-III launch

Key Metrics

MetricQ4 FY24
Revenue₹514 cr, +15% QoQ
EBITDA₹94 cr, +45% QoQ and +7% YoY
EBITDA margin18.4%, +220 bps QoQ
Pharma revenue₹338 cr, EBIT margin 15.9%
Pharma EBIT₹54 cr
Crop protection revenue₹177 cr, EBIT margin 7.7%
Crop protection EBIT₹14 cr
Full-year FY24 revenue₹1,785 cr
Full-year FY24 EBITDA₹267 cr, margin 15%, +230 bps YoY
Full-year FY24 Pharma revenue₹1,100 cr, EBIT margin 8.5%
Full-year FY24 Pharma EBIT₹93 cr
Full-year FY24 Crop revenue₹684 cr, EBIT margin ~11%
Full-year FY24 Crop EBIT₹74 cr
Total dividend FY24₹1.2 per share, 60% of face value
CAPEX FY24~₹230 cr, of which ~₹140-145 cr for animal health
CAPEX guidance FY25₹100-120 cr, primarily debottleneck and infra
Pharma capacity utilization~80%
Crop protection capacity utilizationa little below 70%
Asset turns guidance1.1 to 1.3x on total CAPEX
Animal health revenue potential₹300-400 cr over next 4-5 years
CDMO repeat customer share85-90%
Generics repeat customer share~75%
Pharma Q4 FY24 sales growth~10% YoY (per an analyst's math)
Pharma Q4 FY24 profitability growth~50% YoY (per an analyst's math)